Innate immune evasion strategies of influenza viruses

Future Microbiology

Volumn 5, Issue 1, 2010, Pages 23-41

  Hale, Benjamin G ^a   Albrecht, Randy A ^a   García Sastre, Adolfo ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antivirals; Cell signaling; Influenza virus; Interferon NS1; Pandemic; Vaccines

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ALPHA INTERFERON; BETA INTERFERON; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; CRYOPYRIN; DOUBLE STRANDED RNA; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 3; LIVE VACCINE; NONSTRUCTURAL PROTEIN 1; NUCLEOCAPSID PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN P58; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT2 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE E3;

ALPHA HELIX; ANTIVIRAL SUSCEPTIBILITY; CELL DEATH; DISEASE SEVERITY; ENCAPSULATION; EPIDEMIC; HOST CELL; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; INNATE IMMUNITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS PARTICLE; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE;

ORTHOMYXOVIRIDAE;

EID: 75849125661     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.108     Document Type: Review

References (205)

1. Palese P, Shaw ML: Orthomyxoviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1647-1689 (2007).
2. Klenk HD, Cox NJ, Lamb RA et al.: Orthomyxoviridae. In: ICTVdB - The Universal Virus Database. Büchen-Osmond C (Ed.). Columbia University, NY, USA (2004).
3. Infectious Diseases Society of America (IDSA): Avian Influenza (Bird Flu): Implications for Human Disease. (2007).
4. Wright PF, Webster RG: Orthomyxoviruses. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1533-1579 (2007).
5. Nofs S, Abd-Eldaim M, Thomas KV, Toplon D, Rouse D, Kennedy M: Influenza virus A (H1N1) in giant anteaters (Myrmecophaga tridactyla). Emerg. Infect. Dis. 15, 1081-1083 (2009).
6. Lowen AC, Mubareka S, Steel J, Palese P: Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 3, 1470-1476 (2007).
7. Subbarao K, Swayne DE, Olsen CW: Epidemiology and control of human and animal influenza. In: Influenza Virology: Current Topics. Kawaoka Y (Ed.). Caister Academic Press, Norwich, UK, 229-280 (2006).
8. Taubenberger JK, Palese P: The origin and virulence of the 1918 'Spanish' influenza virus. In: Influenza Virology: Current Topics. Kawaoka Y (Ed.). Caister Academic Press, Norwich, UK, 299-322 (2006).
9. Taubenberger JK, Morens DM: 1918 influenza: the mother of all pandemics. Emerg. Infect. Dis. 12, 15-22 (2006).
10. Webster RG: H5 influenza viruses. In: Influenza Virology: Current Topics. Kawaoka Y (Ed.). Caister Academic Press, Norwich, UK, 281-298 (2006).
11. Neumann G, Noda T, Kawaoka Y: Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459, 931-939 (2009).
12. Smith GJ, Vijaykrishna D, Bahl J et al.: Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459, 1122-1125 (2009).
13. Randall RE, Goodbourn S: Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1-47 (2008).
14. Fernandez-Sesm A: The influenza virus NS1 protein: inhibitor of innate and adaptive immunity. Infect. Disord. Drug Targets 7, 336-343 (2007).
15. Fernandez-Sesma A, Marukian S, Ebersole BJ et al.: Influenza virus evades innate and adaptive immunity via the NS1 protein. J. Virol. 80, 6295-6304 (2006).
16. Haye K, Burmakina S, Moran T, Garcia Sastre A, Fernandez-Sesma A: The NS1 protein of a human influenza virus inhibits type I interferon production and the induction of antiviral responses in primary human dendritic and respiratory epithelial cells. J. Virol. 83, 6849-6862 (2009).
17. Price GE, Gaszewska-Mastarlarz A, Moskophidis D: The role of a/b and g interferons in development of immunity to influenza A virus in mice. J. Virol. 74, 3996-4003 (2000).
18. Durbin JE, Fernandez-Sesma A, Lee CK et al.: Type I IFN modulates innate and specific antiviral immunity. J. Immunol. 164, 4220-4228 (2000).
19. McGill J, Heusel JW, Legge KL: Innate immune control and regulation of influenza virus infections. J. Leukoc. Biol. 86, 803-812 (2009).
20. Longhi MP, Trumpfheller C, Idoyaga J et al.: Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206, 1589-1602 (2009).
21. Steinman RM, Hemmi H: Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-58 (2006).
22. Tovey MG, Lallemand C, Thyphronitis G: Adjuvant activity of type I interferons. Biol. Chem. 389, 541-545 (2008).
23. Horimoto T, Fukuda N, Iwatsuki Horimoto K et al.: Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J. Vet. Med. Sci. 66, 303-305 (2004).
24. Kash JC, Tumpey TM, Proll SC et al.: Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 443, 578-581 (2006).
25. Kobasa D, Jones SM, Shinya K et al.: Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445, 319-323 (2007).
26. de Jong MD, Simmons CP, Thanh TT et al.: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203-1207 (2006).
27. Peiris JS, de Jong MD, Guan Y: Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 20, 243-267 (2007).
28. Salomon R, Hoffmann E, Webster RG: Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Natl Acad. Sci. USA 104, 12479-12481 (2007).
29. Szretter KJ, Gangappa S, Lu X et al.: Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 81, 2736-2744 (2007).
30. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM et al.: Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc. Natl Acad. Sci. USA 106, 3455-3460 (2009).
31. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957).
32. Isaacs A, Lindenmann J, Valentine RC: Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 268-273 (1957).
33. Chelbi-Alix MK, Wietzerbin J: Interferon, a growing cytokine family: 50 years of interferon research. Biochimie 89, 713-718 (2007).
34. Bot A, Bot S, Bona CA: Protective role of g interferon during the recall response to influenza virus. J. Virol. 72, 6637-6645 (1998).
35. Turner SJ, Olivas E, Gutierrez A, Diaz G, Doherty PC: Disregulated influenza A virus-specific CD8+ T cell homeostasis in the absence of IFN-g signaling. J. Immunol. 178, 7616-7622 (2007).
36. Mordstein M, Kochs G, Dumoutier L et al.: Interferon-l contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4, e1000151 (2008).
37. Van Hoeven N, Belser JA, Szretter KJ et al.: Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous a interferon to reduce virus shedding. J. Virol. 83, 2851-2861 (2009).
38. Garcia-Sastre A, Egorov A, Matassov D et al.: Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324-330 (1998).
39. Garcia-Sastre A, Durbin RK, Zheng H et al.: The role of interferon in influenza virus tissue tropism. J. Virol. 72, 8550-8558 (1998).
40. Szretter KJ, Gangappa S, Belser JA et al.: Early control of H5N1 influenza virus replication by the type I interferon response in mice. J. Virol. 83, 5825-5834 (2009).
41. Kugel D, Kochs G, Obojes K et al.: Intranasal administration of a interferon reduces seasonal influenza A virus morbidity in ferrets. J. Virol. 83, 3843-3851 (2009).
42. Pichlmair A, Schulz O, Tan CP et al.: RIG I-mediated antiviral responses to single-stranded RNA bearing 5́-phosphates. Science 314, 997-1001 (2006).
43. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR: Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 80, 5059-5064 (2006).
44. Mogensen TH: Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240-273, Table of Contents (2009).
45. Kanneganti TD, Body-Malapel M, Amer A et al.: Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281, 36560-36568 (2006).
46. Allen IC, Scull MA, Moore CB et al.: The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30, 556-565 (2009).
47. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A: Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206, 79-87 (2009).
48. Thomas PG, Dash P, Aldridge JR Jr et al.: The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30, 566-575 (2009).
49. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
50. Kurt-Jones EA, Popova L, Kwinn L et al.: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398-401 (2000).
51. Imai Y, Kuba K, Neely GG et al.: Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008).
52. Lund JM, Alexopoulou L, Sato A et al.: Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101, 5598-5603 (2004).
53. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529-1531 (2004).
54. Kawai T, Akira S: Toll-like receptor and RIG I-like receptor signaling. Ann. NY Acad. Sci. 1143, 1-20 (2008).
55. Yoneyama M, Fujita T: RNA recognition and signal transduction by RIG I-like receptors. Immunol. Rev. 227, 54-65 (2009).
56. Nakhaei P, Genin P, Civas A, Hiscott J: RIG I-like receptors: Sensing and responding to RNA virus infection. Semin. Immunol. (2009).
57. Loo YM, Fornek J, Crochet N et al.: Distinct RIG I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82, 335-345 (2008).
58. Kato H, Takeuchi O, Sato S et al.: Differential roles of MDA5 and RIG I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
59. Yoneyama M, Kikuchi M, Natsukawa T et al.: The RNA helicase RIG I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730-737 (2004).
60. Yoneyama M, Fujita T: Structural mechanism of RNA recognition by the RIG I-like receptors. Immunity 29, 178-181 (2008).
61. Gack MU, Shin YC, Joo CH et al.: TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG I-mediated antiviral activity. Nature 446, 916-920 (2007).
62. Kawai T, Takahashi K, Sato S et al.: IPS-1, an adaptor triggering RIG I- and Mda5- mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
63. Kumar H, Kawai T, Kato H et al.: Essential role of IPS-1 in innate immune responses against RNA viruses. J. Exp. Med. 203, 1795 - 1803 (2006).
64. Bowie AG, Unterholzner L: Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8, 911-922 (2008).
65. Moore CB, Ting JP: Regulation of mitochondrial antiviral signaling pathways. Immunity 28, 735-739 (2008).
66. Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559-568 (2008).
67. Der SD, Zhou A, Williams BR, Silverman RH: Identification of genes differentially regulated by interferon a, b, or g using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623-15628 (1998).
68. Garcia MA, Gil J, Ventoso I et al.: Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 70, 1032-1060 (2006).
69. Silverman RH: Viral encounters with 2́,5́-oligoadenylate synthetase and RNase L during the interferon antiviral response. J. Virol. 81, 12720-12729 (2007).
70. Haller O, Staeheli P, Kochs G: Protective role of interferon-induced Mx GTPases against influenza viruses. Rev. Sci. Tech. 28, 219-231 (2009).
71. Wang X, Hinson ER, Cresswell P: The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2, 96-105 (2007).
72. Lenschow DJ, Lai C, Frias-Staheli N et al.: IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA 104, 1371-1376 (2007).
73. Lai C, Struckhoff JJ, Schneider J et al.: Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J. Virol. 83, 1147-1151 (2009).
74. Hayman A, Comely S, Lackenby A et al.: Variation in the ability of human influenza A viruses to induce and inhibit the IFN-β pathway. Virology 347, 52-64 (2006).
75. Hale BG, Randall RE, Ortin J, Jackson D: The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89, 2359-2376 (2008).
76. Talon J, Salvatore M, O'Neill RE et al.: Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl Acad. Sci. USA 97, 4309-4314 (2000).
77. Falcon AM, Fernandez-Sesma A, Nakaya Y, Moran TM, Ortin J, Garcia-Sastre A: Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. J. Gen. Virol. 86, 2817-2821 (2005).
78. Quinlivan M, Zamarin D, Garcia-Sastre A, Cullinane A, Chambers T, Palese P: Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79, 8431-8439 (2005).
79. Solorzano A, Webby RJ, Lager KM, Janke BH, Garcia-Sastre A, Richt JA: Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 79, 7535-7543 (2005).
80. Steel J, Lowen AC, Pena L et al.: Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83, 1742-1753 (2009).
81. Chambers TM, Quinlivan M, Sturgill T et al.: Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine Vet. J. 41, 87-92 (2009).
82. Ferko B, Stasakova J, Romanova J et al.: Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J. Virol. 78, 13037-13045 (2004).
83. Donelan NR, Basler CF, Garcia-Sastre A: A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of b interferon and is attenuated in mice. J. Virol. 77, 13257-13266 (2003).
84. Richt JA, Lekcharoensuk P, Lager KM et al.: Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J. Virol. 80, 11009-11018 (2006).
85. Vincent AL, Ma W, Lager KM et al.: Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25, 7999-8009 (2007).
86. Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A et al.: Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J. Virol. 81, 11817-11827 (2007).
87. Moltedo B, Lopez CB, Pazos M, Becker MI, Hermesh T, Moran TM: Cutting edge: stealth influenza virus replication precedes the initiation of adaptive immunity. J. Immunol. 183, 3569-3573 (2009).
88. Dauber B, Heins G, Wolff T: The influenza B virus nonstructural NS1 protein is essential for efficient viral growth and antagonizes b interferon induction. J. Virol. 78, 1865-1872 (2004).
89. Donelan NR, Dauber B, Wang X, Basler CF, Wolff T, Garcia-Sastre A: The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF 3 and b interferon promoter activation. J. Virol. 78, 11574-11582 (2004).
90. Talon J, Horvath CM, Polley R et al.: Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74, 7989-7996 (2000).
91. Wang X, Li M, Zheng H et al.: Influenza A virus NS1 protein prevents activation of NF kB and induction of a/b interferon. J. Virol. 74, 11566-11573 (2000).
92. Ludwig S, Wang X, Ehrhardt C et al.: The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J. Virol. 76, 11166-11171 (2002).
93. Guo Z, Chen LM, Zeng H et al.: NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG I. Am. J. Respir. Cell Mol. Biol. 36, 263-269 (2007).
94. Opitz B, Rejaibi A, Dauber B et al.: IFNb induction by influenza A virus is mediated by RIG I which is regulated by the viral NS1 protein. Cell. Microbiol. 9, 930-938 (2007).
95. Mibayashi M, Martinez-Sobrido L, Loo YM, Cardenas WB, Gale M Jr, Garcia-Sastre A: Inhibition of retinoic acid-inducible gene I-mediated induction of b interferon by the NS1 protein of influenza A virus. J. Virol. 81, 514-524 (2007).
96. Genin P, Lin R, Hiscott J, Civas A: Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 29, 3435-3450 (2009).
97. Gack MU, Albrecht RA, Urano T et al.: Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG I. Cell Host Microbe 5, 439-449 (2009).
98. Ozato K, Shin DM, Chang TH, Morse HC 3rd: TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8, 849-860 (2008).
99. Gack MU, Kirchhofer A, Shin YC et al.: Roles of RIG I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc. Natl Acad. Sci. USA 105, 16743-16748 (2008).
100. Urano T, Saito T, Tsukui T et al.: EFP targets 14-13-3 s for proteolysis and promotes breast tumour growth. Nature 417, 871-875 (2002).
101. Zou W, Zhang DE: The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J. Biol. Chem. 281, 3989-3994 (2006).
102. Nemeroff ME, Barabino SM, Li Y, Keller W, Krug RM: Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3́ end formation of cellular pre-mRNAs. Mol. Cell 1, 991-1000 (1998).
103. Kochs G, Garcia-Sastre A, Martinez Sobrido L: Multiple anti-interferon actions of the influenza A virus NS1 protein. J. Virol. 81, 7011-7021 (2007).
104. Noah DL, Twu KY, Krug RM: Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3́ end processing of cellular pre-mRNAS. Virology 307, 386-395 (2003).
105. Twu KY, Noah DL, Rao P, Kuo RL, Krug RM: The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J. Virol. 80, 3957-3965 (2006).
106. Fortes P, Beloso A, Ortin J: Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J. 13, 704-712 (1994).
107. Lu Y, Qian XY, Krug RM: The influenza virus NS1 protein: a novel inhibitor of pre-mRNA splicing. Genes Dev. 8, 1817-1828 (1994).
108. Li Y, Chen ZY, Wang W, Baker CC, Krug RM: The 3́-end-processing factor CPSF is required for the splicing of single-intron pre-mRNAs in vivo. RNA 7, 920-931 (2001).
109. Das K, Ma LC, Xiao R et al.: Structural basis for suppression of a host antiviral response by influenza A virus. Proc. Natl Acad. Sci. USA 105, 13093-13098 (2008).
110. Twu KY, Kuo RL, Marklund J, Krug RM: The H5N1 influenza virus NS genes selected after 1998 enhance virus replication in mammalian cells. J. Virol. 81, 8112-8121 (2007).
111. Qiu Y, Krug RM: The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A). J. Virol. 68, 2425-2432 (1994).
112. Qian XY, Alonso-Caplen F, Krug RM: Two functional domains of the influenza virus NS1 protein are required for regulation of nuclear export of mRNA. J. Virol. 68, 2433-2441 (1994).
113. Satterly N, Tsai PL, van Deursen J et al.: Influenza virus targets the mRNA export machinery and the nuclear pore complex. Proc. Natl Acad. Sci. USA 104, 1853-1858 (2007).
114. Billharz R, Zeng H, Proll SC et al.: The NS1 protein of the 1918 pandemic influenza virus blocks host interferon and lipid metabolism pathways. J. Virol. 83, 10557-10570 (2009).
115. Plotch SJ, Bouloy M, Ulmanen I, Krug RM: A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 23, 847-858 (1981).
116. Guilligay D, Tarendeau F, Resa-Infante P et al.: The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat. Struct. Mol. Biol. 15, 500-506 (2008).
117. Sugiyama K, Obayashi E, Kawaguchi A et al.: Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J. 28, 1803-1811 (2009).
118. Dias A, Bouvier D, Crepin T et al.: The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458, 914-918 (2009).
119. Yuan P, Bartlam M, Lou Z et al.: Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458, 909-913 (2009).
120. Kuo RL, Krug RM: Influenza A virus polymerase is an integral component of the CPSF30-NS1A protein complex in infected cells. J. Virol. 83, 1611-1616 (2009).
121. Uetani K, Hiroi M, Meguro T et al.: Influenza A virus abrogates IFN-g response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur. J. Immunol. 38, 1559-1573 (2008).
122. Pauli EK, Schmolke M, Wolff T et al.: Influenza A virus inhibits type I IFN signaling via NF kB-dependent induction of SOCS-3 expression. PLoS Pathog. 4, e1000196 (2008).
123. Pothlichet J, Chignard M, Si-Tahar M: Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG I/IFNAR1-dependent pathway. J. Immunol. 180, 2034-2038 (2008).
124. Seo SH, Hoffmann E, Webster RG: Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat. Med. 8, 950-954 (2002).
125. Katze MG, Tomita J, Black T, Krug RM, Safer B, Hovanessian A: Influenza virus regulates protein synthesis during infection by repressing autophosphorylation and activity of the cellular 68,000-Mr protein kinase. J. Virol. 62, 3710-3717 (1988).
126. Lee TG, Tomita J, Hovanessian AG, Katze MG: Purification and partial characterization of a cellular inhibitor of the interferon-induced protein kinase of Mr 68,000 from influenza virus-infected cells. Proc. Natl Acad. Sci. USA 87, 6208-6212 (1990).
127. Lee TG, Tomita J, Hovanessian AG, Katze MG: Characterization and regulation of the 58,000-dalton cellular inhibitor of the interferon-induced, dsRNA-activated protein kinase. J. Biol. Chem. 267, 14238-14243 (1992).
128. Melville MW, Hansen WJ, Freeman BC, Welch WJ, Katze MG: The molecular chaperone hsp40 regulates the activity of P58IPK, the cellular inhibitor of PKR. Proc. Natl Acad. Sci. USA 94, 97-102 (1997).
129. Melville MW, Tan SL, Wambach M, Song J, Morimoto RI, Katze MG: The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity. J. Biol. Chem. 274, 3797-3803 (1999).
130. Li S, Min JY, Krug RM, Sen GC: Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 349, 13-21 (2006).
131. Dauber B, Martinez-Sobrido L, Schneider J et al.: Influenza B virus ribonucleoprotein is a potent activator of the antiviral kinase PKR. PLoS Pathog. 5, e1000473 (2009).
132. Dauber B, Schneider J, Wolff T: Double-stranded RNA binding of influenza B virus nonstructural NS1 protein inhibits protein kinase R but is not essential to antagonize production of α/β interferon. J. Virol. 80, 11667-11677 (2006).
133. Yuan W, Krug RM: Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 20, 362-371 (2001).
134. Chang YG, Yan XZ, Xie YY et al.: Different roles for two ubiquitin-like domains of ISG15 in protein modification. J. Biol. Chem. 283, 13370-13377 (2008).
135. Dittmann J, Stertz S, Grimm D et al.: Influenza A virus strains differ in sensitivity to the antiviral action of Mx-GTPase. J. Virol. 82, 3624-3631 (2008).
136. Rolling T, Koerner I, Zimmermann P et al.: Adaptive mutations resulting in enhanced polymerase activity contribute to high virulence of influenza A virus in mice. J. Virol. 83, 6673-6680 (2009).
137. Grimm D, Staeheli P, Hufbauer M et al.: Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc. Natl Acad. Sci. USA 104, 6806-6811 (2007).
138. Kurokawa M, Koyama AH, Yasuoka S, Adachi A: Influenza virus overcomes apoptosis by rapid multiplication. Int. J. Mol. Med. 3, 527-530 (1999).
139. Zhirnov OP, Klenk HD: Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 12, 1419-1432 (2007).
140. Zhirnov OP, Konakova TE, Wolff T, Klenk HD: NS1 protein of influenza A virus down-regulates apoptosis. J. Virol. 76, 1617-1625 (2002).
141. Ehrhardt C, Wolff T, Pleschka S et al.: Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J. Virol. 81, 3058-3067 (2007).
142. Shin YK, Li Y, Liu Q, Anderson DH, Babiuk LA, Zhou Y: SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation. J. Virol. 81, 12730-12739 (2007).
143. Xing Z, Cardona CJ, Adams S et al.: Differential regulation of antiviral and proinflammatory cytokines and suppression of Fas-mediated apoptosis by NS1 of H9N2 avian influenza virus in chicken macrophages. J. Gen. Virol. 90, 1109-1118 (2009).
144. Ehrhardt C, Wolff T, Ludwig S: Activation of phosphatidylinositol 3-kinase signaling by the nonstructural NS1 protein is not conserved among type A and B influenza viruses. J. Virol. 81, 12097-12100 (2007).
145. Mao H, Tu W, Qin G et al.: Influenza virus directly infects human natural killer cells and induces cell apoptosis. J. Virol. (2009) (Epub ahead of print).
146. Chen W, Calvo PA, Malide D et al.: A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7, 1306-1312 (2001).
147. Gibbs JS, Malide D, Hornung F, Bennink JR, Yewdell JW: The influenza A virus PB1 F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J. Virol. 77, 7214-7224 (2003).
148. Yamada H, Chounan R, Higashi Y, Kurihara N, Kido H: Mitochondrial targeting sequence of the influenza A virus PB1 F2 protein and its function in mitochondria. FEBS Lett. 578, 331-336 (2004).
149. Chanturiya AN, Basanez G, Schubert U, Henklein P, Yewdell JW, Zimmerberg J: PB1 F2, an influenza A virus-encoded proapoptotic mitochondrial protein, creates variably sized pores in planar lipid membranes. J. Virol. 78, 6304-6312 (2004).
150. Zamarin D, Garcia-Sastre A, Xiao X, Wang R, Palese P: Influenza virus PB1 F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog. 1, e4 (2005).
151. Lamb RA, Takeda M: Death by influenza virus protein. Nat. Med. 7, 1286-1288 (2001).
152. Zamarin D, Ortigoza MB, Palese P: Influenza A virus PB1 F2 protein contributes to viral pathogenesis in mice. J. Virol. 80, 7976-7983 (2006).
153. Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P: A single mutation in the PB1 F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog. 3, 1414-1421 (2007).
154. McAuley JL, Hornung F, Boyd KL et al.: Expression of the 1918 influenza A virus PB1 F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2, 240-249 (2007).
155. Schultz-Cherry S, Hinshaw VS: Influenza virus neuraminidase activates latent transforming growth factor β. J. Virol. 70, 8624-8629 (1996).
156. Morris SJ, Price GE, Barnett JM, Hiscox SA, Smith H, Sweet C: Role of neuraminidase in influenza virus-induced apoptosis. J. Gen. Virol. 80 (Pt 1), 137-146 (1999).
157. Zhirnov OP, Ksenofontov AL, Kuzmina SG, Klenk HD: Interaction of influenza A virus M1 matrix protein with caspases. Biochemistry (Mosc.) 67, 534-539 (2002).
158. Gannage M, Dormann D, Albrecht R et al.: Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe 6, 367-380 (2009).
159. Zhou Z, Jiang X, Liu D et al.: Autophagy is involved in influenza A virus replication. Autophagy 5, 321-328 (2009).
160. Fernandez-Sesma A: The influenza virus NS1 protein: inhibitor of innate and adaptive immunity. Infect. Disord. Drug Targets 7, 336-343 (2007).
161. Phipps-Yonas H, Seto J, Sealfon SC, Moran TM, Fernandez-Sesma A: Interferon-b pretreatment of conventional and plasmacytoid human dendritic cells enhances their activation by influenza virus. PLoS Pathog. 4, e1000193 (2008).
162. Borderia AV, Hartmann BM, Fernandez Sesma A, Moran TM, Sealfon SC: Antiviral-activated dendritic cells: a paracrine-induced response state. J. Immunol. 181, 6872-6881 (2008).
163. Lopez CB, Garcia-Sastre A, Williams BR, Moran TM: Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J. Infect. Dis. 187, 1126-1136 (2003).
164. Romanova J, Krenn BM, Wolschek M et al.: Preclinical evaluation of a replication-deficient intranasal DNS1 H5N1 influenza vaccine. PLoS ONE 4, e5984 (2009).
165. Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P: Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82, 10580-10590 (2008).
166. Wressnigg N, Voss D, Wolff T et al.: Development of a live-attenuated influenza B DNS1 intranasal vaccine candidate. Vaccine 27, 2851-2857 (2009).
167. CDC: Update: influenza activity - United States, September 28, 2008-April 4, 2009, and composition of the 2009-2010 influenza vaccine. MMWR Morb. Mortal. Wkly Rep. 58, 369-374 (2009).
168. Le MT, Wertheim HF, Nguyen HD et al.: Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 3, e3339 (2008).
169. Le QM, Kiso M, Someya K et al.: Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108 (2005).
170. Itoh Y, Shinya K, Kiso M et al.: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (2009) (Epub ahead of print).
171. CDC: Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly Rep. 58, 433-435 (2009).
172. Krug RM, Aramini JM: Emerging antiviral targets for influenza A virus. Trends Pharmacol. Sci. 30(6), 269-277 (2009).
173. Hoffmann HH, Palese P, Shaw ML: Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res. 80, 124-134 (2008).
174. Ludwig S: Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 64, 1-4 (2009).
175. Kochs G, Koerner I, Thiel L et al.: Properties of H7N7 influenza A virus strain SC35M lacking interferon antagonist NS1 in mice and chickens. J. Gen. Virol. 88, 1403-1409 (2007).
176. Min JY, Krug RM: The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2́ 5́ oligo (A) synthetase/RNase L pathway. Proc. Natl Acad. Sci. USA 103, 7100-7105 (2006).
177. Hale BG, Jackson D, Chen YH, Lamb RA, Randall RE: Influenza A virus NS1 protein binds p85b and activates phosphatidylinositol- 3-kinase signaling. Proc. Natl Acad. Sci. USA 103, 14194-14199 (2006).
178. Basu D, Walkiewicz MP, Frieman M, Baric RS, Auble DT, Engel DA: Novel influenza virus NS1 antagonists block replication and restore innate immune function. J. Virol. 83, 1881-1891 (2009).
179. Bornholdt ZA, Prasad BV: X-ray structure of NS1 from a highly pathogenic H5N1 influenza virus. Nature 456, 985-988 (2008).
180. Bornholdt ZA, Prasad BV: X-ray structure of influenza virus NS1 effector domain. Nat. Struct. Mol. Biol. 13, 559-560 (2006).
181. Hale BG, Barclay WS, Randall RE, Russell RJ: Structure of an avian influenza A virus NS1 protein effector domain. Virology 378, 1-5 (2008).
182. Liu J, Lynch PA, Chien CY, Montelione GT, Krug RM, Berman HM: Crystal structure of the unique RNA-binding domain of the influenza virus NS1 protein. Nat. Struct. Biol. 4, 896-899 (1997).
183. Xia S, Monzingo AF, Robertus JD: Structure of NS1A effector domain from the influenza A/Udorn/72 virus. Acta Crystallogr. D Biol. Crystallogr. 65, 11-17 (2009).
184. Yin C, Khan JA, Swapna GV et al.: Conserved surface features form the double-stranded RNA binding site of non-structural protein 1 (NS1) from influenza A and B viruses. J. Biol. Chem. 282, 20584-20592 (2007).
185. Cheng A, Wong SM, Yuan YA: Structural basis for dsRNA recognition by NS1 protein of influenza A virus. Cell Res. 19, 187-195 (2009).
186. Chien CY, Tejero R, Huang Y et al.: A novel RNA-binding motif in influenza A virus non-structural protein 1. Nat. Struct. Biol. 4, 891-895 (1997).
187. Maroto M, Fernandez Y, Ortin J, Pelaez F, Cabello MA: Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein. J. Biomol. Screen. 13, 581-590 (2008).
188. Naito T, Kiyasu Y, Sugiyama K et al.: An influenza virus replicon system in yeast identified Tat-SF1 as a stimulatory host factor for viral RNA synthesis. Proc. Natl Acad. Sci. USA 104, 18235-18240 (2007).
189. Hao L, Sakurai A, Watanabe T et al.: Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454, 890-893 (2008).
190. Beilharz MW, Cummins JM, Bennett AL: Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem. Biophys. Res. Commun. 355, 740-744 (2007).
191. Steel J, Staeheli P, Mubareka S, Garcia Sastre A, Palese P, Lowen AC: Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J. Virol. (2009) (Epub ahead of print).
192. Kobiyama K, Takeshita F, Ishii KJ et al.: A signaling polypeptide derived from an innate immune adaptor molecule can be harnessed as a new class of vaccine adjuvant. J. Immunol. 182, 1593-1601 (2009).
193. Lau YF, Tang LH, Ooi EE: A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27, 1354-1364 (2009).
194. Friedman RM: Clinical uses of interferons. Br. J. Clin. Pharmacol. 65, 158-162 (2008).
195. Hayman A, Comely S, Lackenby A et al.: NS1 proteins of avian influenza A viruses can act as antagonists of the human α/β interferon response. J. Virol. 81, 2318-2327 (2007).
196. Lipatov AS, Kwon YK, Sarmento LV et al.: Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. PLoS Pathog. 4, e1000102 (2008).
197. Weingartl HM, Albrecht RA, Lager KM et al.: Experimental infection of pigs with the human 1918 pandemic influenza virus. J. Virol. 83, 4287-4296 (2009).
198. Tumpey TM, Basler CF, Aguilar PV et al.: Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310, 77-80 (2005).
199. Tumpey TM, Maines TR, Van Hoeven N et al.: A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 315, 655-659 (2007).
200. Russell RJ, Kerry PS, Stevens DJ et al.: Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl Acad. Sci. USA 105, 17736-17741 (2008).
201. Malakhov MP, Aschenbrenner LM, Smee DF et al.: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50, 1470-1479 (2006).
202. Belser JA, Lu X, Szretter KJ et al.: DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 196, 1493-1499 (2007).
203. Baas T, Baskin CR, Diamond DL et al.: An integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J. Virol. 80(21), 10813-10828 (2006).
204. Ghanem A, Mayer D, Chase G et al.: Peptide-mediated interference with influenza A virus polymerase. J. Virol. 81, 7801-7804 (2007).
205. Furuta Y, Takahashi K, Shiraki K et al.: T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82, 95-102 (2009).